Vaxart, Inc. Available-for-sale Securities, Gross Realized Gains (Losses), Sale Proceeds (Deprecated 2018-01-31)
Vaxart, Inc. (VXRT) reported Available-for-sale Securities, Gross Realized Gains (Losses), Sale Proceeds (Deprecated 2018-01-31) of $0 for the 9-month period ending 2012-09-30, per its 10-Q filed 2012-11-08.
Discontinued › Income Statement › Other Income
us-gaap:AvailableForSaleSecuritiesGrossRealizedGainsLossesSaleProceeds · last filed 2012-11-08
- Vaxart, Inc. available-for-sale securities, gross realized gains (losses), sale proceeds (deprecated 2018-01-31) for the quarter ending 2012-09-30 was $0.00.
| Period end | Available-for-sale Securities, Gross Realized Gains (Losses), Sale Proceeds (Deprecated 2018-01-31) 3 month | Available-for-sale Securities, Gross Realized Gains (Losses), Sale Proceeds (Deprecated 2018-01-31) 6 month | Available-for-sale Securities, Gross Realized Gains (Losses), Sale Proceeds (Deprecated 2018-01-31) 9 month |
|---|---|---|---|
| 2012-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2012-11-08 | $0.00 10-Q · filed 2012-11-08 | |
| 2012-06-30 | $0.00 10-Q · filed 2012-08-09 | ||
| 2011-09-24 | $0.00 10-Q · filed 2012-11-08 | ||
| 2011-06-25 | $0.00 10-Q · filed 2012-08-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kalaris Therapeutics, Inc. (KLRS) | United States | $0.073B | -2.19 |
| Atara Biotherapeutics, Inc. (ATRA) | United States | $0.086B | -6.48 |
| Pelthos Therapeutics Inc. (PTHS) | United States | $0.086B | -1.20 |
| CHAMPIONS ONCOLOGY, INC. (CSBR) | United States | $0.070B | -68.02 |
| COGNITION THERAPEUTICS INC (CGTX) | United States | $0.090B | -6.52 |
| BioStem Technologies, Inc. (BSEM) | United States | $0.069B | |
| Eloxx Pharmaceuticals, Inc. (ELOX) | United States | $0.065B | |
| MiNK Therapeutics, Inc. (INKT) | United States | $0.063B | -5.37 |
| Cardiff Oncology, Inc. (CRDF) | United States | $0.101B | -2.22 |
| EXOZYMES INC. (EXOZ) | United States | $0.058B |